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Abstract:  The development of animal models of dengue virus (DENV) infection and 
disease has been challenging, as epidemic DENV does not naturally infect non-human 
species. Non-human primates (NHPs) can sustain viral replication in relevant cell types 
and develop a robust immune response, but they do not develop overt disease. In contrast, 
certain immunodeficient mouse models infected with mouse-adapted DENV strains show 
signs of severe disease similar to the ‘vascular-leak’ syndrome seen in severe dengue in 
humans. Humanized mouse models can sustain DENV replication and show some signs of 
disease, but further development is needed to validate the immune response. Classically, 
immunocompetent mice infected with DENV do not manifest disease or else develop 
paralysis when inoculated intracranially; however, a new model using high doses of DENV 
has recently been shown to develop hemorrhagic signs after infection. Overall, each 
model  has its advantages and disadvantages and is differentially suited for studies of 
dengue pathogenesis and immunopathogenesis and/or pre-clinical testing of antiviral drugs 
and vaccines. 
Keywords:  animal models; dengue virus; pathogenesis; immunopathogenesis; antiviral 
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1. Introduction 
Dengue is the most prevalent arthropod-borne viral illness in humans, with half of the world’s 
population at risk for infection and up to 50 million cases of dengue estimated each year [1]. Most 
prevalent in tropical and sub-tropical areas of Latin America and South/Southeast Asia, dengue 
continues to spread into new areas. Outbreaks occurred in 2009 and 2010 in the Key West islands in 
Florida [2], and sporadic autochthonous cases were reported in the Mediterranean region, in southern 
France and Croatia in 2010 [3,4]. Finally, endemic areas have been reported in the Eastern 
Mediterranean [5,6]. Dengue is caused by four DENV serotypes, DENV-1-4, which circulate 
concomitantly in different regions of the world. They are transmitted by Aedes aegypti and 
Ae. albopictus mosquitoes, the latter of which has become endemic in the Southern part of the US [7], 
prompting the re-classification of DENV as a Category A pathogen. DENV is a member of the 
Flaviviridae family and is related to yellow fever virus (YFV), hepatitis C virus (HCV), and the West 
Nile (WNV), Japanese (JEV), and St. Louis encephalitis viruses. 
Human infection with DENV results in either asymptomatic or symptomatic disease, ranging from 
classical dengue fever (DF) to more severe cases of dengue hemorrhagic fever (DHF) and dengue 
shock syndrome (DSS). DF is a self-limited, though incapacitating, febrile illness accompanied by 
retro-orbital pain, headache, skin rash and bone and muscle pain. The hallmark of the more severe 
forms of the disease is a vascular leak syndrome. In the case of DHF, hemorrhagic manifestations, low 
platelet count, and signs of vascular leak, such as increased hematocrit level or pleural effusion, 
accompany the symptoms of DF. Evidence of hypotension, signs of shock, and circulatory failure 
indicate progression to DSS [8]. The WHO has recently revised its classification schema [6], which 
now consists of Dengue With or Without Warning Signs and Severe Dengue. Overall, this new 
classification is helpful for clinical management of potentially severe cases [9,10], but the very broad 
definition of Severe Dengue complicates studies of dengue pathogenesis [10].  
Development of a suitable animal model for DENV infection has been hampered by the low level 
or lack of replication of DENV clinical isolates in wild-type (WT) mice and the lack of clinical disease 
in non-human primates (NHPs). Initial models in mice used intracranial (i.c.) high-dose injections of 
neurovirulent DENV strains into suckling mice [11] and into adult immunocompetent mice, which 
induced neurological disease and paralysis [12]. Peripheral replication of DENV in mice was first 
reported by intravenous (i.v.) and sub-cutaneous (s.c.) infection using a mouse deficient for both 
IFN- and - receptors in a 129 background (AG129) [13]. Generation of mouse-adapted strains 
improved this model, allowing study of pathogenesis [14–16] and testing of therapeutic antibodies 
(Abs) and other antiviral compounds [14,17–20]. The engraftment of human hematopoietic progenitors 
in immunodeficient mice allowed the development of humanized mice, facilitating infection with 
clinical DENV isolates and approximating dengue-like illness [21–24]. Although NHPs do not develop 
any clinical signs of disease, DENV infects relevant cells, and this model is useful for investigating the 
immune response to DENV infection and for testing vaccines in pre-clinical trials. We will discuss the 
advantages and disadvantages of each model and review the applications for which each model has 
been used thus far. 
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2. Animal Models Used for Dengue Tropism and Pathogenesis Studies 
Clinical manifestations of DENV infection and disease severity vary according to different factors: 
(1) host, including genetic, factors; (2) features related to the virus, including virulence and cellular 
tropism; (3) immune response, including both protective and enhancing responses. Manipulation of the 
virus and the host has allowed the development of animal models suitable for pathogenesis studies.  
2.1. DENV Tropism and Severe Disease Manifestations in Humans 
DENV is delivered intradermally (i.d.) through a mosquito bite and initially infects dendritic cells 
(DCs) and macrophages. The use of Abs directed against NS3, a non-structural DENV protein, 
allowed the study of DENV tropism by identifying cells in which active DENV replication was 
occurring [25]. Macrophages and dendritic cells (DCs) were infected in human autopsy specimens, 
both in the spleen and lymph nodes [25]. Similarly in mice, NS3 was detected in phagocytes of the 
spleen and lymph nodes and myeloid cells in bone marrow [25]. These cells migrate to the lymph 
nodes where DENV replicates before spreading to the rest of the body. Bone marrow myeloid cells 
and hepatocytes in liver were also found to be infected [25]. These findings are consistent with 
previous studies of tropism in human autopsies using Abs directed to the DENV E protein [26–33]. 
These findings are also consistent with observations in NHPs showing that mononuclear phagocytes 
are the site of viral replication in vivo [34]. In a mouse model of Ab-enhanced DENV infection, DENV 
replication in sinusoidal endothelial cells in the liver was reported [16], though the relevance to human 
disease has yet to be established. 
Clinical signs of dengue include fever, rash, thrombocytopenia (platelet count ≤ 100,000 cells/mm
3), 
elevated liver enzymes, bleeding and plasma leakage. Thrombocytopenia is one of the major signs of 
DENV infection, and can help with differential diagnosis, especially in young children [35]. 
Thrombocytopenia can be found across the spectrum of disease, from DF to DSS, but platelet counts 
lower than 50,000 cells/mm
3 are considered a sign of severe disease, and severe thrombocytopenia 
correlates with vascular leak syndrome [36,37]. The mechanism of thrombocytopenia has not yet been 
elucidated, and several causes have been explored: Platelet-associated IgG [38]; auto-immunity with 
anti-platelet Abs, eventually resulting in thrombotic microangiopathy [39,40]; and disseminated 
intra-vascular coagulation (DIC) [41]. Decrease in platelet count has also been attributed to bone 
marrow suppression, induced early after infection and before onset of fever, and to hemophagocytosis 
after defervescence [42]. 
Hemorrhagic manifestations can be the consequence of either thrombocytopenia or vascular 
damage. Studies of capillaries in skin biopsies from patients with DHF show marked distortion and 
swelling, but severely damaged vessels are not observed [43]. In vitro infection of endothelial 
cells [44–46] has also been reported, although the in vivo significance of these findings is not entirely 
clear [25]. Thrombomodulin is a marker of endothelial damage, which increases in patients with 
DIC [47] and in DENV-infected patients [48]. The development of DIC during DENV infection is still 
controversial. While the amount of fibrinogen is often reported as decreased during DENV infection, 
prothrombin time (PT) is only moderately increased [37]. In addition, fibrinolysis can be secondary 
to  plasminogen activation, and DENV has been shown to directly activate plasminogen [49]. Viruses 2012, 4 
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Additionally, anti-plasminogen Abs have been found to correlate with hemorrhagic manifestations 
during DENV infection [50,51]. Finally, anti-NS1 Abs, directed against the secreted non-structural 
NS1 protein, have been shown to cross-react with different coagulation components and cells, such as 
endothelial cells, platelets and fibrinogen [105,107].  
The exact cause of vascular leak, which peaks at defervescence and can lead to hypovolemic shock, 
is unknown. A cytokine storm with increase in TNF and a dysregulation of the immune system have 
been shown to participate in the pathogenesis of DENV-induced vascular leak [52]. Activation of 
complement and complement anaphylatoxins can also induce vasodilation and vascular leak [53]. 
Glycosaminoglycans, which include heparan sulfate, a receptor for DENV adhesion, are negatively-
charged polysaccharides, which constitute a physical and electrostatic barrier against leakage of 
protein from the vascular wall. Disruption of glycosaminoglycans or neutralization of their negative 
charge via binding of cationic proteins have been proposed to be involved in the pathogenesis of 
DENV-induced vascular leak [54]. Finally, activation of platelet-activating factor (PAF), has been 
shown to induce vascular permeability [55].  
Overall, while DENV tropism has been defined in both human and animal models, the main site of 
viral replication is still elusive. In addition, the exact mode of pathogenesis of severe disease remains 
unclear and several mechanisms appear to be implicated in the development of hemorrhagic 
manifestations and vascular leak syndrome. 
2.2. NHP Models of DENV Infection 
Studies using WNV have shown that mosquitoes inoculate between 10
4 and 10
6 PFU of WNV per 
bite [56], and similar levels of transmission have been assumed for DENV; thus, infection of animals 
with 10
4–10
6 PFU of DENV is usually considered to mimic the inoculum in a mosquito bite. After 
subcutaneous (s.c.) inoculation with a dose of 10
5 PFU of DENV, NHPs can sustain viral replication; 
however, viral replication is much lower than in humans, is limited to lymphoid-rich tissues, and is 
accompanied by lymphadenopathy, lymphocytosis and leukopenia [57]. Interestingly, the use of 
cyclophosphamide, an alkylating agent and immunosuppressive drug that primarily affects 
proliferating cells and induces lymphopenia, enabled DENV infection of monocytes in Rhesus 
monkeys for prolonged periods [34]. Some Rhesus macaques occasionally displayed low platelet 
counts, but no other overt clinical signs after s.c. DENV infection were observed [58,59]. More 
recently, inoculation with a higher dose of DENV via an intravenous (i.v.) route induced hemorrhage 
and coagulopathy [60]. Monkeys showed hemorrhagic signs by day 3 post-infection, including 
petechiae and hematomas, coagulopathy with increased D-dimers related to DIC, but no other signs 
such as fever, anorexia or lethargy [60]. Thus, a high inoculum of DENV injected i.v. in Rhesus 
macaques can induce hemorrhagic signs reminiscent of hemorrhagic manifestations seen in humans 
and could potentially be used for pre-clinical testing of therapeutic interventions specifically targeting 
DENV-associated coagulopathy. 
2.3. Mouse Models 
The initial mouse models of dengue did not reflect clinical signs of human DENV infection but 
rather developed neurotropic disease, which is not generally observed in humans [11,12]. WT Viruses 2012, 4 
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immunocompetent mice, including A/J, BALB/c and C57BL/6 mice, support some level of DENV 
replication. A/J and BALB/c mice ultimately succumb from paralysis [61,62]. DENV infection in 
these mice induced limited DENV-specific pathogenesis such as liver damage, as defined by increased 
liver enzymes, increased white blood cell (WBC) counts, thrombocytopenia, and an increase in 
hematocrit level reminiscent of vascular leak [62–64]. DHF-like disease has been reported in BALB/c 
mice with high doses of a highly adapted virus strain [55,61]. Hemorrhagic signs were also observed in 
C57BL/6 mice after infection with very high doses of DENV (3 × 10
9 PFU of DENV-2 strain 16681) 
injected intra-dermally (i.d.) in 4 different injection points [65,66]. In addition, in this model the 
authors demonstrated DENV infection of endothelial cells [65]. Infection of these immunocompetent 
mice with high doses (3  ×  10
9 pfu/mL) of DENV can also induce endothelial damage and tissue 
hemorrhage without overt signs of disease [66]. 
Severe combined immunodeficiency (SCID) mice lack both humoral and cellular responses due to 
deficiencies in B and T cell development. These mice can sustain xeno-grafts and have been used to 
study several other viral infections that otherwise lack a suitable small animal model [42]. SCID mice 
are engrafted with tumor cells prior to DENV infection, and DENV is inoculated into the engrafted 
cells. While DENV can replicate efficiently in SCID tumor models, including K562-engrafted SCID 
mice [67], Huh7-engrafted SCID mice [68] or HepG2-engrafted SCID mice [69], DENV infects 
mainly the engrafted-tumor cells and virus then spreads to the brain, inducing paralysis. Thus, this 
model is not relevant for tropism and pathogenesis studies, but can be useful for drug and vaccine 
testing (see below).  
As DENV infects human cells better than mouse cells, another approach has been the development 
of humanized mice, i.e., mice engrafted with human progenitor cells, such as CD34
+ cells. SCID mice 
can easily be engrafted with tumor cells; however, engraftment of human tissues in these mice is not 
optimal due to a strong innate immune response, including Natural Killer (NK) cells, which hinders 
engraftment of hematopoietic tissues. Therefore, SCID mice were backcrossed with non-obese diabetic 
(NOD) mice, which have defects in NK cell function and a deficiency in hemolytic complement 
response due to the lack of C5, and subsequently with IL2R-knock-out (KO) mice. The combination 
of a deficient innate and adaptive immune response allows better engraftment of a variety of human 
cells and tissues. Reconstitution of NOD/SCID/IL2RKO mice with CD34
+ human progenitor cells 
enables the development of different human cells in the mouse, including DCs, one of the main targets 
of DENV infection [21,23,24]. DENV infects human cells in different mouse tissues, including spleen, 
bone marrow and liver, all tissues relevant to DENV pathogenesis. After DENV infection, these mice 
develop clinical signs of DF including fever, erythema and thrombocytopenia [23,24], although no 
severe disease has been reported yet [23,24]. The advantage of these mice is the possibility of studying 
the human immune response in vivo. However, so far it has been difficult to generate a sustained and 
sufficient Ab production [23,24]. Although Ab production is difficult to obtain, these mice usually 
develop a DENV-specific T cell response [70], making it a useful model to study the role of 
cross-reactive T cells in sequential infections. In contrast, RAG-hu mice, which lack both RAG and 
IL2R genes, developed fever but no other signs of disease using a pool of four different low-passage 
DENV-2 clinical isolates or one lab-adapted DENV-2. Interestingly, most of these RAG/IL2R 
mice (10 of 16) developed anti-DENV Abs, and 3 of them demonstrated neutralizing Abs [22]. Viruses 2012, 4 
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Infection of AG129 mice by DENV clinical isolates induces neurological disease, as seen in other 
models [13,71]. However, using a mouse-adapted DENV-2 strain designated D2S10, a vascular leak 
syndrome was induced in AG129 mice, reminiscent of the severe disease seen in humans [15]. The 
increased virulence of DENV-2 D2S10 has been attributed to mutations in the heparin sulfate-binding 
domain of the envelope (E) protein that reduce the rate of viral clearance from the periphery [72]. 
Subsequently, a triple-plaque-purified clone of DENV-2 D2S10, designated S221, which contains an 
additional mutation in NS1, was reported to cause morbidity in A129 mice, lacking only the IFN-/ 
receptor. Additional passage in mice of DENV-2 D2S10 led to selection of another mutation in the 
heparan-binding region of E and resulted in a virus that causes lethal disease in 129 or C57/BL6 mice 
lacking only the IFN-/ receptor [73]. Another group reported signs of severe disease, including liver 
damage, hemorrhagic signs, and vascular permeability, in BALB/c mice using a highly mouse-adapted 
DENV-2 strain [55], although the mutations responsible for this increased virulence have not yet been 
identified. Recently, non-mouse adapted DENV isolates have been shown to induce severe disease in 
immunocompromised mice. Infection of AG129 mice intraperitoneally (i.p.) with a variable dose 
(10
2 to 10
7 pfu) of the DENV-2 strain D2Y98P (passage 20) induced dose-dependent symptoms, with 
the development of either non-severe or severe disease, characterized by increased hepatic enzymes 
and disrupted splenic architecture, with no neurological disease [74]. A mutation in NS4B was later 
identified as responsible for the virulence and disease severity induced by this virus [75].  
3. Animal Models Used for Immunopathogenesis Studies of Dengue  
Epidemiological studies have demonstrated a clear correlation between severe disease and 
secondary DENV infection with a distinct DENV serotype [76–79]. Under certain conditions, 
cross-reactive anti-DENV Abs can induce Ab-dependent enhancement (ADE) of infection, resulting in 
more severe disease [80,81]. ADE increases viral load by enhancing viral infection of   
Fc receptor-bearing cells [14]. Cross-reactive T cells likely contribute to immunopathogenesis of 
severe disease by participating in a pro-inflammatory cascade, with cross-reactive T cells producing 
higher levels of TNF and IFN- than homotypic T cells, leading to dysregulation of cytokine 
production [52,82,83]. In spite of this situation, most of secondary DENV infections in humans are 
either asymptomatic or manifest as classic DF. Thus, the adaptive immune response is not only 
implicated in immunopathogenesis but can also induce effective protection. The factors that distinguish 
cross-protective immunity from immunopathogenesis are not clearly understood and remain one of the 
main questions to be answered in order to understand the pathogenesis of severe disease as well as the 
mechanisms of protection, which could potentially contribute to better vaccine design. 
3.1. NHP Models 
NHPs do not develop any clinical signs of disease; however, they do develop an Ab immune 
response similar to the immune response seen in humans [57]. In humans, primary infection with each 
of the 4 DENV serotypes induces a broadly cross-reactive Ab and T cell response, though the response 
is directed mainly against the infecting serotype [17,84,85]. Cross-reactivity with multiple serotypes is 
common, especially at epitopes in the more highly conserved NS proteins or conserved epitopes 
in E, but can vary among different epitopes and depending on the degree of homology found within Viruses 2012, 4 
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each  DENV serotype/genotype [17,99,100]. Interestingly, sequential infections in NHPs induced 
a  cross-reactive response, with the highest Ab titers directed against the primary infecting 
serotype  [86,87], reminiscent of what has been shown in humans and mice and termed “original 
antigenic sin” [88–92]. Viremia increases after a secondary DENV infection in NHPs, suggesting that 
ADE may increase viral load through cross-reactive Abs [59]. Similarly, after passive transfer of 
anti-DENV monoclonal Ab 1A5 prior to DENV infection, viremia increased 3- to 100-fold in Rhesus 
macaques, though no signs of disease were apparent  [93]. T cell responses have been less well 
characterized in NHP models. One report demonstrated cross-reactivity of T cells upon DENV 
infection, with higher responses directed towards the primary infecting serotype [87], mirroring what 
has been reported in humans, where hyper-activation of low-affinity memory T cells induced during 
the primary DENV infection  participate  in  the immunopathogenesis of DHF and DSS [52,94]. 
In  summary,  while  increased viremia can be demonstrated in NHP models, the animals do not 
develop vascular leak or syndromes resembling DHF or DSS, thus limiting their use in the study of 
pathogenesis/immunopathogenesis. 
3.2. Mouse Models 
AG129 mice, though partially immunocompromised, develop a broadly cross-reactive and 
long-lasting Ab response to DENV [95]. Sequential DENV infection in this mouse model results in 
decreased viral load of the second serotype [95] as well as full protection against lethal infection [91]. 
In addition, T cells have been shown to play a role in protection, as DENV-1-immune mice depleted of 
T cells prior to a DENV-2 D2S10 lethal infection developed clinical signs of disease [91]. Thus far, 
the conditions for modeling severe disease after a sequential DENV infection have not yet been 
established, but will be a great addition for the study of immunopathogenesis induced by cross-reactive 
T cells. In contrast, ADE has been achieved in AG129 and other mouse strains by passive transfer of 
anti-DENV monoclonal Abs, cross-reactive immune serum, or diluted homotypic serum prior to 
infection [14,16,73]. Mice previously primed with anti-DENV serum develop increased viral load in 
the serum and several tissues and succumb after infection with a sub-lethal dose of DENV (10
5 PFU 
DENV-2 D2S10 i.v.). A vascular leak syndrome, increased serum levels of TNF and IL-10, and low 
platelet counts precede death [14], signs that are reminiscent of DHF and DSS. All these signs are also 
induced in a direct lethal model using a 10
7 PFU dose of DENV-2 D2S10, suggesting that 
pathogenesis is triggered by high viral load [15], whether this high viral load has been induced by a 
high DENV inoculum or has been achieved through ADE. Of note, mice receiving passive transfer of 
serum or Ab do not have a memory response to DENV. It is possible that inducing ADE in the 
presence of a memory response may be more restricted, and models of sequential DENV infection may 
be useful to study ADE in the presence of a cellular memory immune response. Overall, the amount of 
neutralizing Ab seems to be critical for the induction of protection or ADE [14]. Humoral memory 
response to DENV in humans has been shown to wane over time [77], and the time elapsed between 
the primary and secondary infection may be a key component in the development of severe disease [80]. 
Mouse models are not ideally suited to address this question due to the limited lifespan of a mouse; 
however, development of NHP models would be useful to study this issue. Other key questions that are 
under investigation are identification of Ab epitopes that are more likely to induce protection versus Viruses 2012, 4 
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ADE, as well as which serotype sequences are more associated with increased disease severity. While 
epitope specificity may vary between humans and mice, we have shown that human Abs can induce 
ADE in mice [17], paving the way towards analysis of human serum in mice [96].  
The role of cross-reactive T cells in mouse models is beginning to be explored. Homotypic CD8
+ T 
cells have been shown to protect against an infection with the same serotype [97]. In contrast, CD4
+ T 
cells can help CD8
+ T cell responses after vaccination but are not necessary for Ab production and 
CD8
+ T cell response after primary infection [98]. Using a tumor-engrafted SCID mouse model, T 
cells have been shown to have both protective and pathogenic roles, inducing either an accelerated 
death (80% of infected mice) or full recovery from disease (in 20% of the mice) after transfer of 
DENV-specific T cells [69]. Similarly to what has been described in humans, sequential infections of 
BALB/c mice induced a cross-reactive CD8
+ T cell response, which was higher against the first 
infecting serotype [99]. The magnitude of this T cell response as well as the immunodominant epitope 
response varied with the sequence of infecting DENV serotypes. However, direct transposition to 
humans may be difficult as immunodominant epitopes may be different in mice and humans. The 
preferential activation of cross-reactive T cells during secondary infection in mice induced higher 
levels of TNF responses, suggesting participation of cross-reactive T cells in the immunopathogenesis 
of vascular leak syndrome [99]. Cross-reactive CD4
+ T cells have also been shown to increase 
cross-reactive CD8
+ T cell responses in this mouse model, suggesting that they may also participate in 
the immunopathogenesis of severe disease [100]. As with Ab epitopes, T cell epitopes may play 
differential roles in protection and enhancement, as shown recently in a C57BL/6 model [101]. While 
these mouse models have shed light on the activation of cross-reactive T cells during secondary DENV 
infection, none of the mice developed severe disease; thus, a mouse model that supports both viral 
replication and natural T cell responses and reproduces features of severe disease is needed to better 
characterize the role of the T cell response during secondary DENV infection and vascular leak. To 
this end, we have recently developed a new mouse-adapted strain that induces lethal disease in 
IFNAR1
−/− mice (lacking only the IFN-receptor) in both 129 and C57/BL6 backgrounds, setting 
the stage for potential T cell studies [73]. Recently, a new model to study DENV-specific human T cell 
responses in mice has been established by back-crossing HLA transgenic mice into the IFNAR1
−/− 
background. Immunodominant T cell epitopes relevant for human studies have been identified using 
this model [102].  
NS1 is a non-structural DENV protein that is secreted from infected cells and found attached to the 
cell surface during DENV infection. The amount of circulating NS1 has been correlated with more 
severe disease [103], though whether this is due to a direct effect of NS1 or a reflection of higher 
viremia is not fully understood. Soluble and membrane-bound NS1 have been shown to induce 
complement activation, increasing vascular leakage [104]. Anti-NS1 Abs have also been shown to play 
a pathogenic role [105], as some Abs cross-react with endothelial cells and platelets, potentially 
inducing both thrombocytopenia and vascular leak [105]. In addition, damage of endothelial cells in 
the liver induced by anti-NS1 Abs has been shown to correlate with liver damage and increased 
hepatic enzymes in mice [106]. Anti-E Abs have also been shown to interact with plasminogen, 
inhibiting plasmin activity [107,108]. AG129 mice infected with DENV have high levels of circulating 
NS1 and anti-NS1 Abs [109], making it a good model to study the role of NS1 and anti-NS1 Ab 
in vivo. Viruses 2012, 4 
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4. Animals Models Used for Therapeutic Testing 
No anti-viral drug against DENV has been commercialized so far, and only supportive care, 
including fluid replacement, is used for the management of DHF/DSS, requiring hospitalization. A 
number of anti-viral candidates have been tested in mouse models that develop paralysis and 
encephalitis [110–112]; however, the relevance to human disease of drugs that target neurological 
manifestations is not entirely clear, as bioavailability of the drug may be different in the central 
nervous system than in other tissues. An aqueous extract of neem leaves inhibited viral replication and 
prevented clinical signs of disease in suckling mice infected with DENV i.c. [113]. Castanospermine, 
an alpha-glucosidase inhibitor, inhibits the folding of viral proteins and decreases viral secretion and 
has been shown to prevent mortality in A/J mice infected by the i.c. route [112]. Subsequently, this 
same drug, together with other anti-viral compounds, was tested in AG129 mice infected with a 
non-adapted DENV strain (TSV01) and showed efficacy by reducing viral load and decreasing the 
inflammatory response [19]. The non-adapted DENV strain TSV01 is well-suited for measuring the 
effects of potential anti-virals on viremia and has proven useful in demonstrating synergy among 
different anti-viral compounds when using drug combinations [18]. 
The AG129 mouse model infected with mouse-adapted DENV strains, leading to a lethal vascular 
leak syndrome, has also been used for anti-viral testing [19,48,114–117]. Morbidity, mortality, viral 
load, signs of vascular leak, platelet count and levels of pro-inflammatory cytokines, such as TNF, 
can all be used as relevant read-outs for drug efficacy. Recently, the use of siRNA targeting the 
conserved 5' cyclization sequence in the DENV viral RNA genome delayed mortality and substantially 
reduced viral load in several tissues in the AG129 model using ADE-induced infection [118]. We have 
shown using this same model that monoclonal Abs unable to bind to Fc receptors have prophylactic 
and therapeutic activity [14,17]. Thus, immunodeficient mouse models that develop disease features 
resembling human disease are valuable in the development of anti-viral drugs against dengue. 
5. Animals Models Used for Vaccine Testing 
There is no DENV vaccine currently licensed, but numerous vaccines are in development and 
several are in Phase 1/2 of clinical trials. As the immune mechanisms of protection against DENV are 
not fully understood, clear correlates of immune protection are not yet available to monitor vaccine 
efficacy/effectiveness. Neutralizing Abs are important for protection against DENV infection, but the 
amount and characteristics of Ab needed for full protection remain elusive. In addition, animal models 
have demonstrated the contribution of cytotoxic T cells to protection, but further investigation is 
needed in the human system. Because of the risk of developing more severe disease after a secondary 
infection due to cross-reactive Ab or cross-reactive T cells, a successful dengue vaccine needs to 
induce a balanced response against the four serotypes of DENV. Finally, waning immunity can induce 
ADE in the long term as the amount of anti-DENV Abs decrease; thus, induction of long-lasting 
immunity is an issue that must be addressed.  
DENV vaccines developed thus far are either live-attenuated vaccines, inactivated vaccines, 
virus-like particles (VLPs) or subunit vaccines targeting the viral envelope (E), pre-membrane (prM) 
or NS1 proteins [119–122]. Pre-clinical vaccine testing includes evaluation of safety, infectivity (for Viruses 2012, 4 
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the live-attenuated vaccines), immunogenicity and efficacy. Due to the high costs of NHP models, 
mouse models are usually used as a first step for pre-clinical development of vaccines.  
Immunocompetent mice are in general the best-suited models to test the immunogenicity of a 
vaccine and have been proven to be useful for testing subunit vaccines [123–127]. However, DENV 
replication is low in these mice; thus, the immune response induced by live-attenuated vaccines may 
be underestimated due to the low level of viral replication. As discussed above, immunocompetent 
mice, either adult or suckling mice, infected with DENV i.c. develop neurological signs and succumb 
by paralysis. This end-point has been chosen as a read-out to measure vaccine efficacy in several 
studies [65,68,128]. In addition, suckling mice are a good model for safety testing, in order to evaluate 
the potential neurovirulence of live-attenuated dengue vaccines [129]. SCID mice tumor cell models of 
infection have similarly been used to assess vaccine effectiveness by measuring viral load after 
challenge [68,130]. This model has also been used to test attenuation of virulence, as measured by the 
duration and magnitude of the viremia; however, it may be less sensitive than the suckling mouse 
model, as several candidate vaccine strains that were greatly attenuated in the SCID-tumor model were 
not attenuated when tested in NHPs [131]. 
The immunocompromised mouse model AG129 was originally developed for vaccine testing since 
these mice can sustain DENV replication [13], though as initially tested, they succumbed to paralysis. 
Generation of a mouse-adapted DENV strain enabled development of a mouse model that manifests 
signs of severe dengue reminiscent of human disease, including vascular leak [15]. Thus, this model of 
systemic dengue disease may constitute a more satisfactory approach for testing vaccine efficacy. 
However, concerns have been raised regarding the development of a full immune response due to the 
lack of IFN-/ and - receptors. Nevertheless, we have shown that AG129 mice develop 
DENV-specific Abs that are long-lasting and protective against homologous and heterologous viral 
challenge [95]. In addition, we have shown that the IgG isotype composition of the Abs produced by 
AG129 is fairly balanced (IgG1:IgG2a:IgG2b = 1:4:1) and similar to what has been reported in WT 
mice [132]. AG129 mice also develop a strong B cell response, as measured by ELISPOT [91]. The T 
cell response has not been extensively characterized in these mice, as it is known that IFN- is 
necessary for correct recall of the memory T cell response [133]. Despite this, we have shown a certain 
degree of T cell functionality, as depletion of T cells prior to DENV infection induced morbidity, 
while non-depleted mice were fully protected and showed no signs of infection [91]. Despite its 
limitations, the AG129 model has proven to be useful in the testing of a live-attenuated vaccine [134] 
and in testing the immune response to non-structural proteins in a chimeric vaccine [135]. To improve 
the model, we have recently developed a new mouse-adapted strain that induces a vascular leak in 
IFNAR1
−/− mice [73]. As these mice lack only the IFN-/ receptor, they should be more suitable for 
future vaccine testing. 
While the use of NHP models is limited for pathogenesis studies, Rhesus macaques have 
been shown to develop anti-DENV Abs and viremia kinetics closely related to what is observed in 
humans [136]. Thus, the read-out for testing vaccines in NHPs is limited to prevention of viremia after 
challenge and studies on the amount and specificity of the immune response. NHPs have been very 
useful in predicting the infectivity, replication kinetics and immunogenicity of live-attenuated vaccines 
that are now in clinical trial and have been used to achieve the development of a balanced tetravalent 
formulation [137–143].  Viruses 2012, 4 
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6. Conclusion and Future Directions 
The development of a suitable animal model of DENV infection has been hampered by the limited 
infectivity and replication of DENV in non-human species. Mouse and NHP models are available and 
each model can be used for different applications. Further manipulation of the virus or the mouse 
immune system could lead in the future to improved models. For instance, mouse STAT2, in contrast 
to human STAT2, has recently been shown to restrict DENV infection by resisting degradation 
mediated by DENV NS5 [144]. Thus, engineering a human STAT2 transgenic mouse could allow the 
development of an immunocompetent mouse model permissive to DENV infection. New models, such 
as the use of HLA transgenic mice or the study of human Abs in mice, as well as progress in 
humanized mice, will allow a better understanding of the human immune response to dengue in an 
in vivo situation. Each model has its advantages and disadvantages; thus, each model should be 
carefully chosen for different studies, including pathogenesis/immunopathogenesis, development of 
the immune response, drug testing or vaccine evaluation.  
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